IVF Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

In vitro fertilization (IVF) is the most effective and widely practiced assisted reproductive technology (ART), combining a woman's eggs with sperm in an embryology laboratory to create embryos that are then transferred to the uterus. Approximately 2.5 million IVF cycles are performed globally each year, resulting in over 500,000 births annually. Since Louise Brown—the first IVF baby—was born in 1978, IVF has led to more than 8 million live births worldwide.

The IVF process consists of five key phases. First, ovarian stimulation: injectable gonadotropins (FSH, LH, or both) for 10–14 days stimulate the ovaries to produce multiple mature follicles instead of the single egg released in a natural cycle. Follicle development is monitored by serial transvaginal ultrasound and serum estradiol measurements every 2–3 days. Second, ovulation triggering: when follicles reach optimal size (18–20 mm), a trigger injection of hCG or GnRH agonist (leuprolide) initiates final oocyte maturation. Third, transvaginal oocyte retrieval: performed under conscious sedation or general anesthesia 36 hours after the trigger, using a needle passed through the vaginal wall into each follicle to aspirate the egg-containing follicular fluid. Fourth, fertilization and embryo culture: eggs are fertilized by standard insemination or intracytoplasmic sperm injection (ICSI), where a single sperm is injected directly into each mature egg. Embryos are cultured for 3–6 days, ideally to blastocyst stage. Optionally, preimplantation genetic testing (PGT-A or PGT-M) is performed on a trophectoderm biopsy at Day 5–6. Fifth, embryo transfer: one or two embryos are transferred through the cervix into the uterus under ultrasound guidance, a painless procedure requiring no sedation. Surplus good-quality embryos are vitrified for future frozen embryo transfer (FET) cycles.

IVF is indicated for a broad spectrum of infertility diagnoses spanning both female and male factor causes. Tubal factor infertility—bilateral tubal occlusion, severe tubal damage from prior ectopic pregnancy or PID, or prior salpingectomy—is the original indication for IVF, bypassing the tubes entirely. Severe male factor infertility (oligozoospermia <5 million/mL, asthenozoospermia, azoospermia requiring surgically retrieved sperm) is treated with IVF combined with ICSI, which requires only a single viable sperm per egg.

Unexplained infertility failing three or more IUI cycles with ovarian stimulation, endometriosis-associated infertility (Stage III–IV with distorted pelvic anatomy or recurrent implantation failure), polycystic ovary syndrome (PCOS) refractory to ovulation induction and IUI, and diminished ovarian reserve (where maximizing egg numbers per stimulation cycle is critical) are all major IVF indications. Premature ovarian insufficiency (POI) is treated with donor egg IVF, achieving live birth rates independent of recipient age.

Recurrent implantation failure (three or more failed transfers of good-quality embryos) warrants thorough uterine evaluation and may involve IVF with PGT-A to select euploid embryos. Recurrent pregnancy loss with chromosomal contributions is addressed by PGT-A or PGT-SR (for structural rearrangements). Genetic disease risk—for couples carrying monogenic disorders such as cystic fibrosis, sickle cell disease, Huntington's disease, or BRCA1/BRCA2 mutations—is managed with IVF plus PGT-M (preimplantation genetic testing for monogenic disorders), allowing selection of unaffected embryos. Same-sex couples and single parents by choice use IVF with donor sperm, donor eggs, or a gestational carrier according to their specific family-building needs.

There is no absolute upper age limit for IVF in most jurisdictions, but live birth rates using own eggs decline substantially after age 38 and are markedly lower after 42. Advanced maternal age (AMA, ≥35) patients should not delay IVF evaluation. Uterine evaluation by saline infusion sonography (SIS) or hysteroscopy is recommended before IVF to identify and correct cavity abnormalities (polyps, submucosal fibroids, Asherman adhesions) that impair implantation. Semen analysis determines the need for ICSI versus standard insemination. Ovarian reserve assessment (AMH, Day 3 FSH and estradiol, antral follicle count) guides stimulation protocol and expected response.

PGT-A is most beneficial in AMA patients (≥37 years), those with recurrent implantation failure, recurrent pregnancy loss, or severe male factor infertility. For PGT-A, embryo biopsy is performed at blastocyst stage, with results available within 1–2 weeks; only euploid (chromosomally normal) embryos are transferred, reducing miscarriage risk from 20–40% to 5–10% per transfer and improving implantation efficiency.

Contraindications to IVF include active, untreated malignancy (embryo or egg cryopreservation is performed pre-treatment instead), severe uncorrected uterine abnormality (Asherman syndrome requiring hysteroscopic treatment first), major medical instability precluding ovarian stimulation or sedation, and active untreated sexually transmitted infection. Women with extremely poor ovarian reserve (AMH <0.5 ng/mL, AFC <3) may attempt IVF but must be counseled about low expected egg yield and the option of donor egg IVF. Women over 43 should receive proactive counseling about the dramatically reduced probability of live birth with own eggs and the substantially better outcomes of donor egg IVF.

IVF begins with controlled ovarian stimulation (COS) using daily subcutaneous FSH injections (150–450 IU daily, adjusted by monitoring) over 10–14 days to recruit multiple follicles. A GnRH agonist or antagonist protocol suppresses premature LH surge. When leading follicles reach 17–18 mm, hCG or GnRH agonist trigger induces final oocyte maturation. Transvaginal ultrasound-guided egg retrieval is performed 36 hours later under IV sedation.

In the embryology laboratory, retrieved eggs are assessed for maturity — only MII (metaphase II) oocytes are fertilised. Standard insemination or ICSI is performed; fertilisation is confirmed at 16–18 hours. Embryos develop in time-lapse incubators (EmbryoScope) over 5–6 days, assessed by morphokinetic parameters. Top-quality blastocysts are transferred (fresh or vitrified for FET).

Freeze-all strategy: all embryos vitrified, transferred in a subsequent hormonally prepared FET cycle — allows OHSS prevention, PGT-A testing, and optimal endometrial timing. PGT-A (preimplantation genetic testing for aneuploidies): trophectoderm biopsy of day 5–6 blastocysts, next-generation sequencing identifies chromosomally normal embryos for transfer — reducing miscarriage by 50% in high-risk groups. Donor egg IVF for diminished ovarian reserve: synchronised donor stimulation with recipient endometrial preparation, embryo transfer to recipient uterus. Dual stimulation (DuoStim): two stimulation rounds in a single cycle for poor responders to maximise egg numbers before fertility preservation or treatment deadlines.

IVF offers the highest per-cycle live birth rates of any assisted reproductive technology. SART (Society for Assisted Reproductive Technology) and CDC annual reports document the following live birth rates per embryo transfer using own eggs: under 35 years: 40–50%; 35–37 years: 30–40%; 38–39 years: 20–30%; 40–42 years: 10–20%; above 42 years: 5–10%. Donor egg IVF dramatically improves outcomes regardless of recipient age: live birth rates from donor egg programs are 45–55% per transfer, independent of whether the recipient is 35 or 50.

PGT-A substantially reduces miscarriage rates—from 20–40% without testing to 5–10% per transfer—by ensuring only euploid embryos are transferred, particularly benefiting AMA women and those with prior losses. Cumulative live birth rates after multiple IVF cycles are substantially higher than single-cycle rates: after 3–4 complete cycles (fresh plus all FET), cumulative live birth rates approach 70–80% for women under 38 in well-managed programs.

ICsi for severe male factor infertility achieves fertilization rates of 60–80%, comparable to standard IVF in couples with normal sperm parameters. Freeze-all strategies—vitrifying all embryos and transferring in a subsequent optimized FET cycle—achieve equivalent or superior outcomes to fresh transfer while nearly eliminating severe OHSS risk. AID systems using closed-loop technology for T1DM patients in IVF programs have demonstrated the safety of IVF in well-controlled diabetes. For oncofertility patients, embryo cryopreservation after IVF before cancer treatment preserves reproductive potential with higher reliability than egg freezing alone, as embryos survive thawing at higher rates (95%+) than oocytes (80–90%).

Ovarian hyperstimulation syndrome (OHSS) is the most significant acute complication of IVF stimulation. Mild-to-moderate OHSS (bloating, nausea, abdominal discomfort, mild ascites) occurs in 10–20% of stimulated cycles and resolves spontaneously with supportive care. Severe OHSS—rapid fluid accumulation in the abdomen and pleural cavity, hemoconcentration, electrolyte imbalances, and thromboembolism risk—occurs in 1–3% of cycles and may require hospitalization, albumin infusion, or ascitic drainage. GnRH antagonist protocols with GnRH agonist trigger and freeze-all strategy have substantially reduced severe OHSS rates. PCOS patients and those with high AFC are at highest risk.

Multiple pregnancy—historically the major IVF safety concern—has decreased significantly with the widespread adoption of elective single embryo transfer (eSET) policy in most developed countries. Twin rates from IVF with sSET are now 5–10% (primarily from splitting of a single embryo), down from 30%+ in the 1990s. Multiple pregnancies increase risks of preterm birth, low birth weight, preeclampsia, gestational diabetes, and neonatal complications.

Ectopic pregnancy occurs in 2–3% of IVF pregnancies, higher than spontaneous rates, particularly in women with prior tubal disease. Egg retrieval carries a small risk of intraperitoneal bleeding (<0.5%), pelvic infection (<0.3%), and adjacent organ injury (bladder, bowel—rare, <0.1%). Miscarriage occurs in 15–20% of IVF pregnancies for women under 35, rising to 40–50% for women over 40 due to age-related aneuploidy. Large epidemiological studies show a modest increase in birth defect prevalence (5.8% vs. 4.4% in spontaneous conception), possibly reflecting underlying infertility rather than IVF procedures themselves. Psychological stress from repeated treatment failures is clinically significant and requires structured psychological support throughout the IVF journey.

After egg retrieval, patients rest for 2–4 hours before discharge. Mild pelvic discomfort, bloating, and light spotting are normal for 3–5 days. Strenuous activity and intercourse are avoided for 5–7 days. Progesterone supplementation begins the evening of retrieval for fresh ET cycles or on designated start day for FET cycles.

Embryo development updates are communicated daily by the embryology team — fertilisation check (day 1), cleavage assessment (day 3), blastocyst report (day 5–6). If all embryos are vitrified (freeze-all), transfer scheduling is discussed with the reproductive endocrinologist. Endometrial preparation for FET typically takes 3–4 weeks.

Beta-hCG pregnancy test is performed 12–14 days after embryo transfer. Positive results require repeat hCG at 48 hours to confirm doubling, then transvaginal ultrasound at 6–7 weeks. OHSS monitoring is essential in the 5–10 days after retrieval — patients with significant bloating, weight gain exceeding 2 kg in 24 hours, reduced urine output, or severe abdominal pain should contact their clinic immediately. Annual cumulative outcome review with the reproductive endocrinologist is recommended for those with multiple failed cycles to reassess diagnosis and adjust the treatment strategy.

IVF costs vary enormously by country, with medical tourism offering savings of 60–80% compared to US pricing. In the United States, a single fresh IVF cycle including monitoring, egg retrieval, ICSI, embryo culture, and one fresh transfer typically costs $12,000–$20,000 for the procedure alone, with stimulation medications adding $3,000–$6,000. Frozen embryo transfer (FET) adds $3,000–$5,000 per cycle. PGT-A adds $3,000–$6,000 for biopsy and sequencing. Donor egg IVF in the US costs $25,000–$40,000 total. Some US states mandate insurance coverage for IVF (currently 21 states have infertility coverage laws), but coverage scope and cycle limits vary significantly.

In India, a complete IVF cycle including ICSI and medications is available at $2,000–$4,500 at internationally accredited fertility centers in Mumbai, Delhi, Bengaluru, Chennai, and Hyderabad. Donor egg IVF in India costs $3,500–$7,000. Thailand offers IVF packages at $3,500–$7,000 per cycle at JCI-accredited hospitals in Bangkok, with excellent laboratory standards. Spain and Cyprus—leading European fertility tourism destinations—charge €4,000–€8,000 per IVF cycle, with donor egg IVF at €5,000–€9,000. Czech Republic and Poland offer highly competitive European IVF at €2,500–€5,000. The UK NHS covers one to three IVF cycles for eligible patients (criteria include age limits and prior children), with private IVF at £5,000–£9,000 per cycle including medications. Israel offers highly subsidized IVF for women up to age 45 for up to four children under the national health system.

Intrauterine insemination (IUI) with or without ovarian stimulation is the appropriate first-line ART for unexplained infertility, mild male factor, or anovulation — achieving 8–15% live birth rate per cycle. Three to six IUI cycles are recommended before escalation to IVF. Laparoscopic surgery for tubal or peritoneal factor may restore natural fertility before IVF is considered.

For poor ovarian responders who achieve very few eggs with conventional stimulation, in vitro maturation (IVM) matures immature oocytes retrieved from antral follicles with minimal stimulation — reducing OHSS risk. Ovarian rejuvenation procedures (platelet-rich plasma ovarian injection, stem cell therapy) are experimental and not yet evidence-based for clinical use. For couples averse to IVF, natural cycle IVF (no stimulation medications, one egg retrieved in a natural cycle) avoids medications but achieves lower success rates of 5–10% per cycle. Donor egg IVF is the most effective alternative for diminished ovarian reserve (DOR) or repeated IVF failure with own eggs — live birth rates of 55–65% per transfer irrespective of recipient age.